HREC Approval Accelerates Global Phase 3 DFI Strategy
Filed with ASX · · 4 pages · English
Summary by 6ix AI
The trial is being conducted to US FDA regulatory standards and has already treated a portion of the anticipated patient population. This development supports Recce's global regulatory strategy targeting approvals across multiple markets, including Australia and the United States.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Recce Pharmaceuticals Ltd. on 6ix
Earlier from Recce Pharmaceuticals
- Addendum to Recce Signs Middle East Licensing Term Sheet
- Recce Signs Middle East Licensing Term Sheet
- Brazil Patent Granted for RECCE Anti-Infectives
- RCE Investor Webinar Presentation Deck
- Appendix 4D and Interim Financial Report
Later from Recce Pharmaceuticals
- Placement & SPP to raise $8 million
- AUD $3.7M Income Tax Refund Received
- Vietnamese Patent Granted for RECCE Anti-Infectives
- HREC Approves Comparator Study for Pivotal Phase 3 DFI
- Appendix 4E and FY26 Annual Report
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals